Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), 13005 Marseille, France.
Viruses. 2020 Jun 8;12(6):624. doi: 10.3390/v12060624.
Clinical samples collected in coronavirus disease 19 (COVID-19), patients are commonly manipulated in biosafety level 2 laboratories for molecular diagnostic purposes. Here, we tested French norm NF-EN-14476+A2 derived from European standard EN-14885 to assess the risk of manipulating infectious viruses prior to RNA extraction. SARS-CoV-2 cell-culture supernatant and nasopharyngeal samples (virus-spiked samples and clinical samples collected in COVID-19 patients) were used to measure the reduction of infectivity after 10 minute contact with lysis buffer containing various detergents and chaotropic agents. A total of thirteen protocols were evaluated. Two commercially available formulations showed the ability to reduce infectivity by at least 6 log 10, whereas others proved less effective.
临床样本采集于新型冠状病毒病(COVID-19)患者,通常在生物安全二级实验室中进行分子诊断操作。在此,我们测试了源自欧洲标准 EN-14885 的法国标准 NF-EN-14476+A2,以评估在 RNA 提取之前操作传染性病毒的风险。我们使用 SARS-CoV-2 细胞培养上清液和鼻咽样本(病毒感染样本和 COVID-19 患者采集的临床样本)来测量在与含有各种清洁剂和变性剂的裂解缓冲液接触 10 分钟后感染性的降低。共评估了 13 种方案。两种市售配方显示出至少降低 6 个对数的感染能力,而其他配方效果较差。